Abstract
Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76†0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69†0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72†0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
| Original language | English |
|---|---|
| Pages (from-to) | 249-257.e1 |
| Journal | Alzheimer's and Dementia |
| Volume | 11 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1 Mar 2015 |
| Externally published | Yes |
Bibliographical note
Funding Information:Three-City Study: The Three-City (3C) Study was performed as part of a collaboration among the Institut National de la Santé et de la Recherche Médicale (INSERM), the Victor Segalen-Bordeaux II University, and Sanofi-Synthelabo. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salariés , Direction Générale de la Santé , MGEN , Institut de la Longevité , Agence Francaise de Securité Sanitaire des Produits de Santé , the Aquitaine and Bourgogne Regional Councils , Fondation de France , and the joint French Ministry of Research / National Institute of Health and Medical Research “Cohortes et collections de données biologiques” program. Lille Génopole received an unconditional grant from Eisai . This work was additionally funded by the CNRS , the Nord Pas-de-Calais Regional Council , and the European Regional Development Fund , and grants from INSERM-DHOS-INCA (Project A08037ECS) and the European Community's cNEUPRO programme (contract LSHM-CT-2007-037950).
Funding Information:
Honolulu Asia Aging Study: This work was supported by the National Institutes of Health (National Institute on Aging contract NO1-AG-4-2149, cooperative agreements 5U01AG017155-09 and 5U01AG019349-08, and the Intramural Research Program of the National Institutes of Health and with resources at the Veterans Affairs Pacific Islands Health Care System).
Funding Information:
This work was supported by the dedication of the Framingham Heart Study participants.
Funding Information:
Framingham Heart Study: This work received support from the National Heart, Lung and Blood Institute 's Framingham Heart Study (contract no. N01-HC-25195) and grants from the National Institute of Neurological Disorders and Stroke ( NS17950 ) and the National Institute on Aging ( AG08122 , AG16495 , and AG033193 ).
Publisher Copyright:
© 2015 The Alzheimer's Association.
Keywords
- Alzheimer's disease
- Aβ peptides
- Epidemiology
- Framingham
- Heart
- Incident
- Incident dementia
- Meta-analysis
- Plasma biomarker
- Study
ASJC Scopus subject areas
- Epidemiology
- Health Policy
- Developmental Neuroscience
- Clinical Neurology
- Geriatrics and Gerontology
- Psychiatry and Mental health
- Cellular and Molecular Neuroscience
